drugset / Trial / NCT00519012

Benefits of Switching Antidepressants Following Early Nonresponse

NCT00519012

Phase 4 Unknown 200 enrolled Oizumi Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Introduction and Purpose: Most of the guidelines for the treatment of major depression recommend the use of antidepressants for 4 to 8 weeks. On the other hand, it has been recently reported that they start to show their antidepressant efficacy within a couple of weeks (1,2), contrary to the conventional theory. In addition, a good response (i.e. a 20% reduction in the Montgomery-Åsberg Depression Rating Scale \[MADRS\]) at week 2 is proposed to be a predictor of subsequent remission at week 6 (3,4), while nonresponse at week 2 could predict unfavourable outcome at week 8 (5). Furthermore, early worsening is suggested to be related to a low rate of remission at weeks 8 and 12(6).

Timeline

Start
2007-08
Primary completion
2010-12
Completion
2010-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Paroxetine Small molecule 20 mg
Comparator Paroxetine Small molecule 40 mg
Comparator Sertraline Small molecule 50 mg
Comparator Sertraline Small molecule 100 mg

Indications